Skip to main content

Advertisement

Table 4 CTCAE grade ≥3 adverse events observed in more than 5% of patients

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

  Platinum combination therapy (n = 24) Docetaxel monotherapy (n = 61)  
Grade 3 Grade 4 Total (%) Grade 3 Grade 4 Total (%) p value*
Leukocytopenia 8 2 10 (41.6) 30 9 39 (63.9) 0.06
Neutropenia 8 6 14 (58.3) 16 28 44 (72.1) 0.08
Anemia 3 0 3 (12.5) 2 0 2 (3.3) 0.12
Febrile neutropenia 2 0 2 (8.3) 6 0 6 (9.8) 0.82
Anorexia 1 0 1 (4.2) 5 0 5 (8.2) 0.49
Infection 1 0 1 (4.2) 3 0 3 (4.9) 0.88
  1. Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events version 3.0.
  2. *Fisher’s exact test.